Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cybin Inc (HELP)

Cybin Inc (HELP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 427,072
  • Shares Outstanding, K 50,067
  • Annual Sales, $ 0 K
  • Annual Income, $ -81,310 K
  • EBIT $ -118 M
  • EBITDA $ -117 M
  • 60-Month Beta 0.61
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.39

Options Overview Details

View History
  • Implied Volatility 147.80% (-95.44%)
  • Historical Volatility 74.12%
  • IV Percentile 51%
  • IV Rank 26.73%
  • IV High 353.04% on 03/02/26
  • IV Low 72.91% on 01/22/26
  • Expected Move (DTE 15) 1.40 (16.44%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 786
  • Volume Avg (30-Day) 1,035
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 18,529
  • Open Int (30-Day) 20,444
  • Expected Range 7.13 to 9.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -1.04
  • Number of Estimates 1
  • High Estimate -1.04
  • Low Estimate -1.04
  • Prior Year -1.02
  • Growth Rate Est. (year over year) -1.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.76 +48.09%
on 02/09/26
8.55 -0.23%
on 03/04/26
+2.17 (+34.12%)
since 02/04/26
3-Month
5.61 +52.05%
on 12/08/25
9.12 -6.47%
on 12/30/25
+2.58 (+43.36%)
since 12/04/25
52-Week
4.81 +77.34%
on 04/07/25
9.83 -13.22%
on 07/01/25
+1.07 (+14.34%)
since 03/04/25

Most Recent Stories

More News
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Statistically significant (p

HELP : 8.53 (+7.97%)
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity

EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END

HELP : 8.53 (+7.97%)
CMPS : 7.05 (+1.44%)
PFE : 26.62 (+0.15%)
TAK : 18.22 (+0.77%)
BMY : 62.33 (+1.81%)
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio   This news release...

HELP : 8.53 (+7.97%)
LLY : 1,003.57 (-0.41%)
PFE : 26.62 (+0.15%)
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news...

HELP : 8.53 (+7.97%)
Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise

See what Compass Pathways’ Phase 3 COMP360 TRD data showed, why the stock jumped, and how a discounted offering reshapes the near-term setup.

HELP : 8.53 (+7.97%)
CMPS : 7.05 (+1.44%)
Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive symptoms as measured by MADRS score (mean difference: -7.35)...

HELP : 8.53 (+7.97%)
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

- Cash position of US$195 million as of December 31, 2025, before adjustment for post quarter events - - Topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder...

HELP : 8.53 (+7.97%)
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END

HELP : 8.53 (+7.97%)
AZN : 201.53 (-0.11%)
JNJ : 245.30 (-0.59%)
HELP.NE : 11.5900 (+9.44%)
ABBV : 236.19 (+1.00%)
TAK : 18.22 (+0.77%)
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution

Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior...

HELP : 8.53 (+7.97%)
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution

Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior...

HELP : 8.53 (+7.97%)

Business Summary

Helus Pharma is a clinical stage pharmaceutical company. Its lead candidate includes HLP003 and HLP004. Helus Pharma, formerly known as Cybin Inc., is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 9.50
2nd Resistance Point 9.02
1st Resistance Point 8.78
Last Price 8.53
1st Support Level 8.06
2nd Support Level 7.58
3rd Support Level 7.34

See More

52-Week High 9.83
Last Price 8.53
Fibonacci 61.8% 7.91
Fibonacci 50% 7.32
Fibonacci 38.2% 6.73
52-Week Low 4.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar